ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > new board member

<< Previous

Bullboard Posts

Next >>

Comment by M101on Jan 18, 2022 3:15pm

119 Views

Post# 34329948

RE:RE:RE:new board member

Lol, that would be too efficient.
But I don't really have a problem with this expansion as Cashman appears to be behind it and it's consistent with the value of the platform in getting more IP ASAP. It's not going to have any effect on the timeline for P1 which is all that matters this year.

<< Previous

Bullboard Posts

Next >>

5 steps to mastering risk management in the stock market